Traders assign an 81.5% probability to no new COVID variant of concern emerging before 2027 because ongoing genomic surveillance shows SARS-CoV-2 continuing to evolve through Omicron sublineages such as XFG without crossing the thresholds for increased transmissibility, severity, or immune escape that would trigger official designation. Recent monitoring reports through April 2026 confirm no variants currently meet variant-of-concern criteria, with strains like BA.3.2 remaining under observation but producing no widespread spikes in hospitalizations or vaccine breakthrough cases. This pattern aligns with the post-Omicron stabilization seen since late 2024, where incremental mutations have prompted routine vaccine updates rather than disruptive new threats.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourOui
$238,975 Vol.
$238,975 Vol.
Oui
$238,975 Vol.
$238,975 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Marché ouvert : Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Traders assign an 81.5% probability to no new COVID variant of concern emerging before 2027 because ongoing genomic surveillance shows SARS-CoV-2 continuing to evolve through Omicron sublineages such as XFG without crossing the thresholds for increased transmissibility, severity, or immune escape that would trigger official designation. Recent monitoring reports through April 2026 confirm no variants currently meet variant-of-concern criteria, with strains like BA.3.2 remaining under observation but producing no widespread spikes in hospitalizations or vaccine breakthrough cases. This pattern aligns with the post-Omicron stabilization seen since late 2024, where incremental mutations have prompted routine vaccine updates rather than disruptive new threats.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes